Imatinib Wockhardt Uk

Imatinib mesylate, the active ingredient in Imatinib Wockhardt Uk, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Wockhardt Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib mesylate is a tyrosine kinase inhibitor used in hematologic and solid‑tumor indications.

- Chronic myeloid leukemia (CML): provides disease control by suppressing the malignant BCR‑ABL clone. - Gastrointestinal stromal tumor (GIST): induces tumor shrinkage and prolongs progression‑free survival. - Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy.

Adverse reactions may occur with any dose of Imatinib.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often of the ankles. - Fatigue: reduced energy levels. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced cardiac output. - Pulmonary hypertension: increased pressure in lung arteries. - Severe hemorrhage: unexpected bleeding events. - Anaphylaxis: acute allergic reaction requiring emergency care.

Patients receiving Imatinib should be monitored for safety and efficacy.

- Blood counts: monitor complete blood count regularly. - Liver function: assess hepatic enzymes before and during therapy. - Cardiac assessment: evaluate cardiac status in patients with pre‑existing heart disease. - Hypersensitivity: discontinue if signs of severe allergic reaction appear. - Drug interactions: review concomitant medications for potential CYP3A4 effects. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase Imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): reduce therapeutic levels. - Antacids containing aluminum or magnesium: may decrease absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - CYP3A4 substrates (e.g., midazolam): possible increased plasma concentrations. - QT‑prolonging agents (e.g., quinidine): monitor cardiac rhythm.